Bank of America Comments on Generic Injectables

Bank of America has conducted an “in-depth analysis of the injectable pharmaceuticals market, which includes: (1) the patent cycle, ie, branded product sales value that may be available to the generic injectable industry over the next 10 years (2011-2020); (2) an assessment of the current generic injectables market environment; (3) a review of mergers and acquisitions in the generic injectable industry, which in keeping with the broader generic pharma trend, continues to consolidate; and (4) a brief summary of current issues (product shortages, manufacturing issues, recalls).” “We note that our analysis is US centric and more about companies than stocks. Moreover, our analysis does not include biologics, which account for a significant and growing portion of the injectable market,” Bank of America writes.